PDF
T/CAMDI 122-2023 Active
General requirements for 3D bioprinted tumor models according to T/CAMDI 122-2023
Abstract
Main technical content: This document specifies the general requirements for 3D bioprinted tumor models. This document is applicable to tumor models constructed based on 3D bioprinting, which are used in basic research on tumors, diagnosis of tumor molecular subtypes, and sensitivity testing of anti-tumor drugs. Drug sensitivity testing may include, but is not limited to, chemotherapy drugs, targeted drugs, immunotherapy drugs, and candidate compounds for new drugs; it can test a single drug or a combination of drugs.
General Product Information
| Document Type | Group standards |
|---|---|
| Standard Status | Active |
| Standard Code | T/CAMDI 122-2023 |
| ICS | Surgical implants, prostheses, and orthoses |
| Implement Date | 2023-12-31 |
Price
$ 20.00
Subtotal
$ 20.00
Tax
$ 0.00
Order Total (incl. tax)
$ 20.00